

## **Supporting Information**

### **“A data fusion framework to enhance association study in epilepsy”,**

**Simone Marini, Ivan Limongelli, Ettore Rizzo, Alberto Malovini, Edoardo Errichiello, Annalisa Vetro, Tan Da, Orsetta Zuffardi, Riccardo Bellazzi**

Supplementary Table A	Page 2
Supplementary Table B	Page 3
List of genes utilized in the panel	Page 4
Sample size analysis, multivariate	Page 9
Sample size analysis, univariate	Page 24
Supplementary Bibliography	Page 27

*Supplementary Table A*

Notes on the expression of the associated genes (source: GeneCards)

<i>Name</i>	<i>Embryogenesis expression in nervous tissues</i>	
<b>SCN1A</b>	Brain (Nervous System)	Forebrain White Matter
<b>CACNA1G</b>	Brain (Nervous System)	Hypothalamus Hippocampus Thalamus Cerebellum Amygdala
<b>CHRNA2</b>	Neural Tube (Nervous System)	Primitive Spinal Cord Telencephalon Diencephalon Metencephalic Alar Plate Metencephalic Basal Plate
	Brain (Nervous System)	Pituitary Gland Cerebellum Striatum Midbrain tegmentum

*Supplementary Table B*

Relevant disorders associated to the associated pathways (source: KEGG)

<i>Name</i>	Description	<i>Relevant associated KEGG diseases</i>
hsa04725	Cholinergic synapse - Homo sapiens (human)	Periodic paralysis Early infantile epileptic encephalopathy Hypokalemic periodic paralysis Familial or sporadic hemiplegic migraine Benign familial neonatal and infantile epilepsies Autosomal dominant nocturnal frontal lobe epilepsy
hsa04728	Dopaminergic synapse - Homo sapiens (human)	Syndromic X-linked mental retardation with epilepsy or seizures Familial or sporadic hemiplegic migraine Febrile seizures Obsessive-compulsive disorder
hsa04020	Calcium signaling pathway - Homo sapiens (human)	Familial or sporadic hemiplegic migraine Neuromuscular disorders (such as Brugada syndrome, Hypokalemic periodic paralysis, Catecholaminergic polymorphic ventricular tachycardia, Brody myopathy, Multi-minicore disease)
hsa04976	Bile secretion - Homo sapiens (human)	GLUT1 deficiency syndrome (resulting in hypoglycorrhachia. Affected individuals present with mental retardation and learning disabilities; also common are ataxia, dystonia, <i>seizures</i> , and acquired microcephaly)
hsa04911	Insulin secretion - Homo sapiens (human)	Defects in the degradation of ganglioside (resulting in the accumulation of undegraded substrates in neurons and skeletal tissues)
hsa04919	Thyroid hormone signaling pathway - Homo sapiens (human)	--
hsa05033	Nicotine addiction - Homo sapiens (human)	--
hsa04930	Type II diabetes mellitus - Homo sapiens (human)	--

*List of genes utilized in the panel*

ALDH7A1

ARAF

ARHGEF9

ARX

ASPM

ATP1A2

BRD2

CACNA1A

CACNA1G

CACNA1G-AS1

CACNA1H

CACNB4

CCM2

CDKL5

CEND1

CHRNA2

CHRNA4

CHRNA2

CLCN2

CLN8

CNTNAP2

CSTB

DCX

DKFZp686K1684

DMD

DYRK1A

EFHC1  
EPM2A  
FANCI  
FLNA  
FOXG1  
GABBR1  
GABRA1  
GABRA6  
GABRD  
GABRG2  
GJD2  
GPR56  
GPR98  
GRIK1-AS2  
GRIN2A  
GRIN2B  
HCN1  
HTT  
HTT-AS1  
IPCEF1  
JRK  
KCNA1  
KCNA2  
KCND2  
KCNJ10  
KCNMA1  
KCNN3  
KCNQ2

KCNQ3  
KCTD7  
KRIT1  
LGI1  
LOC100507463  
LOC729683  
MAGI2  
MECP2  
MIR3911  
MIR548F3  
MIR548I4  
MIR548T  
MLLT3  
NDP  
NEDD4L  
NHLRC1  
NOTCH3  
OPA1  
OPHN1  
OPRM1  
PAFAH1B1  
PAX6  
PCDH19  
PDCD10  
PDYN  
PLCB1  
POLG  
PORCN

PPP2R2C  
PQBP1  
PRICKLE1  
PSMB9  
PTK2B  
RBFOX1  
RELN  
RS1  
SCARB2  
SCN1A  
SCN1B  
SCN2A  
SCN9A  
SERPINI1  
SHANK3  
SLC1A3  
SLC25A22  
SLC2A1  
SLC2A2  
SLC4A10  
SLC4A3  
SRPX2  
ST3GAL5  
STRADA  
STXBP1  
SYN  
SYP  
TAP1

TBC1D24

TCF4

TIMM17B

TPSG1

TUBA1A


UBE3A





### Sample size analysis, multivariate


Multivariate sample size analysis have been calculated via learning curves for each data set, measured for 5, 6, 7, 8, 9, 10, 20 ... 140, 145, 146 samples. For each sample bin, sensitivity has been averaged over 100 repetitions of a 5 fold cross validation. The cutoff line represents sensitivity with the full data set (146 samples), while the red area is the confidence interval at 95%.


Supplementary Figures S1-S15 depict the learning curves for all the data sets.











































### *Sample size analysis, univariate*

The effect of sample size on univariate analysis was calculated with simulations. The following procedure was applied to each feature:

1. Simulate new data based on the variable's distribution observed in cases and controls (mean, standard deviation, number of observations) and estimate the Cohen's effect size as follows:

$$abs(\text{mean group 1} - \text{mean group 2}) / \text{standard deviation (pooled)}$$

where *abs* is the absolute value.

2. Perform a Wilcoxon Rank Sum test to test for the presence of statistically significant differences in terms of the simulated variable's distribution between class = 1 and class = 0 and collect the deriving p-values.

The simulating-and-testing procedure was repeated 1000 times for each variable and the frequency of statistically significant differences (i.e., the number of times the p-value was < 0.05 divided by the number of simulations performed) estimated (statistical power).

Results are reported in the Supplementary Figure 16, describing variations in terms of statistical power distribution obtained from simulations as function of the effect size observed from data, given the number of cases and controls analysed and assuming a significance threshold of  $p < 0.05$ .






Figure S16. Scatterplots reporting variations in terms of statistical power (x-axis) as function of the observed effect size, quantified in terms of Cohen's  $d$  (y-axis) for each dataset. The horizontal dashed lines highlight the thresholds corresponding to  $d$  values of 0.2, 0.5, and 0.8, representing small, medium, and large effect sizes respectively, according to Rosenthal and Rosnow (1984, p.361).

Results (Figure S16 and Table S1) show that the study is sufficiently powered (> 80%) to detect intermediate to large effect sizes ( $0.5 < d < 0.8$ , given the number of cases and controls analysed and assuming a significance threshold of  $p < 0.05$ ).

<b>Cohen's d</b>	<b>Domains</b>	<b>Genes</b>	<b>Pathways</b>	<b>Protein-protein interactions</b>
d < 0.2	0	0	0	0
0.2 < d < 0.5	1.27	2.78	15.38	0.49
0.5 < d < 0.8	100	100	100	100

Table S1. Frequency (%) of features reaching statistical power > 80% by effect size ranges based on simulations.

As shown in Supplementary Figure 16, the required Cohen's d level for achieving 0.8 power is ~0.5. Cohen's d has been measured for each statistically significant ROI, and found in the range [0.57-0.77].

SCN1A Cohen's d estimate:	0.7045188
CHRN2 Cohen's d estimate:	0.6538497
CACNA1G Cohen's d estimate:	0.5975064
IPR001696 Cohen's d estimate:	0.6229835
IPR010526 Cohen's d estimate:	0.6272407
IPR005821 Cohen's d estimate:	0.7059557
IPR001098 Cohen's d estimate:	0.5810361
hsa04930 Cohen's d estimate:	0.7543276
hsa04728 Cohen's d estimate:	0.7756596
hsa04725 Cohen's d estimate:	0.6528608
hsa04919 Cohen's d estimate:	0.572608
hsa04976 Cohen's d estimate:	0.574127
hsa04911 Cohen's d estimate:	0.6966038
hsa05033 Cohen's d estimate:	0.7097573
hsa04020 Cohen's d estimate:	0.7296446
UBC_ppi Cohen's d estimate:	0.7167586
SNTA1_ppi Cohen's d estimate:	0.7288087
PSEN1_ppi Cohen's d estimate:	0.7045188

## **Supplementary References**

Jacob Cohen (1988). *Statistical Power Analysis for the Behavioral Sciences* (second ed.). Lawrence Erlbaum Associates

Rosenthal, R. and R.L. Rosnow (1984), *Essentials of Behavioral Research: Methods and Data Analysis*. New York: McGraw-Hill.